Sonidegib (Erismodegib, NVP-LDE225)
Product #:
TS0875
Image
SKU-Pack Size
Stock
Price($)
Quantity
-
-
TS0875-5MG
In-stock
180
-
+
TS0875-10MG
In-stock
240
-
+
Details
l General Information |
Product Name | Sonidegib |
General description | Sonidegib is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. |
Synonym | Erismodegib,
NVP-LDE225 |
Purity | ≥98.0%(HPLC) | CAS Number | 956697-53-3 |
Formula | C26H26F3N3O3 | Molecular Weight | 485.507 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | ≥50mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Sonidegib is an orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |